Bank of America Raises Oscar Health Price Target Citing Improved Margin Outlook

LONDON, Sept. 17 (Reuters) - Bank of America raised its price target for Oscar Health Inc. on Wednesday, citing a strengthened outlook for the health insurer's profit margins as it navigates a competitive U.S. market.

The investment bank adjusted its valuation for the California-based company, which operates primarily through online platforms to sell health insurance plans, reflecting expectations that operational efficiencies will drive higher profitability in the coming quarters. The move comes as Oscar Health seeks to solidify its position among major insurers following years of expansion and strategic restructuring.

Bank of America analysts highlighted specific improvements in the company's medical cost ratios and administrative expense management as key drivers for the upgrade. The bank noted that Oscar Health has successfully implemented cost-control measures that are beginning to materialize in financial results, suggesting a path toward sustainable growth that was previously uncertain.

The price target increase positions Oscar Health favorably against peers in the managed care sector, where margin compression has been a persistent challenge due to rising healthcare costs and regulatory pressures. By focusing on its digital-first model, the insurer aims to reduce overhead while maintaining customer acquisition rates. The bank's report indicates that these structural advantages could allow Oscar Health to outperform broader market expectations in 2026.

Oscar Health has faced scrutiny in recent years regarding its ability to balance rapid subscriber growth with financial stability. The company previously reported losses as it invested heavily in technology and marketing to capture market share. However, recent quarterly data suggests a turning point, with narrowing losses and improved underwriting results signaling that the turnaround strategy is gaining traction.

The upgrade by Bank of America adds to growing investor confidence in the stock, which has seen volatility tied to macroeconomic factors affecting the healthcare industry. Analysts note that while the margin outlook remains positive, external variables such as changes in government subsidies or shifts in consumer enrollment patterns could still impact performance.

Market participants are now watching closely to see if Oscar Health can sustain its momentum through the remainder of the year. The company's upcoming earnings report will be critical in validating the assumptions behind Bank of America's revised projections. Investors remain divided on whether the current trajectory represents a long-term shift or a temporary correction in an otherwise challenging sector.

As the healthcare insurance landscape evolves, Oscar Health's ability to maintain its margin improvements while scaling operations will determine its future valuation. The bank's updated stance underscores a belief that the company is better positioned than previously thought to deliver returns, though questions remain about the durability of these gains in a fluctuating economic environment.